Vaccines against toxoplasma gondii: challenges and opportunities

Erik Jongert, Craig W Roberts, Nicola Gargano, Elisabeth Förster-Wald, Eskild Petersen

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects. Rodent models have been used in research on vaccines against T. gondii over the past decades. However, regardless of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is challenged with T. gondii, either directly or via a vector. Only a few live, attenuated T. gondii strains used for immunization have been able to confer protective immunity, which is measured by a lack of tissue cysts after challenge. Furthermore, challenge with low virulence strains, especially strains with genotype II, will probably be insufficient to provide protection against the more virulent T. gondii strains, such as those with genotypes I or II, or those genotypes from South America not belonging to genotype I, II or III. Future studies should use animal models besides rodents, and challenges should be performed with at least one genotype II T. gondii and one of the more virulent genotypes. Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to the traditional endpoint of survival or reduction in numbers of brain cysts after challenge.
LanguageEnglish
Pages252-266
Number of pages15
JournalMemorias do Instituto Oswaldo Cruz
Volume104
Issue number2
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Toxoplasma
Vaccines
Genotype
South America
Cysts
Immunity
Rodentia
Eye Diseases
Toxoplasmosis
Virulence
Immunization
Animal Models
Mothers
Survival
Brain
Research
Pharmaceutical Preparations

Keywords

  • toxoplasma gondii
  • vaccine models
  • vaccines
  • virulence
  • genotype

Cite this

Jongert, Erik ; Roberts, Craig W ; Gargano, Nicola ; Förster-Wald, Elisabeth ; Petersen, Eskild. / Vaccines against toxoplasma gondii : challenges and opportunities. In: Memorias do Instituto Oswaldo Cruz. 2009 ; Vol. 104, No. 2. pp. 252-266.
@article{e79b51eb656548a5b5f22d5e18510c9b,
title = "Vaccines against toxoplasma gondii: challenges and opportunities",
abstract = "Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects. Rodent models have been used in research on vaccines against T. gondii over the past decades. However, regardless of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is challenged with T. gondii, either directly or via a vector. Only a few live, attenuated T. gondii strains used for immunization have been able to confer protective immunity, which is measured by a lack of tissue cysts after challenge. Furthermore, challenge with low virulence strains, especially strains with genotype II, will probably be insufficient to provide protection against the more virulent T. gondii strains, such as those with genotypes I or II, or those genotypes from South America not belonging to genotype I, II or III. Future studies should use animal models besides rodents, and challenges should be performed with at least one genotype II T. gondii and one of the more virulent genotypes. Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to the traditional endpoint of survival or reduction in numbers of brain cysts after challenge.",
keywords = "toxoplasma gondii, vaccine models, vaccines, virulence, genotype",
author = "Erik Jongert and Roberts, {Craig W} and Nicola Gargano and Elisabeth F{\"o}rster-Wald and Eskild Petersen",
year = "2009",
month = "3",
doi = "10.1590/S0074-02762009000200019",
language = "English",
volume = "104",
pages = "252--266",
journal = "Memorias do Instituto Oswaldo Cruz",
issn = "1678-8060",
publisher = "Fundacao Oswaldo Cruz",
number = "2",

}

Vaccines against toxoplasma gondii : challenges and opportunities. / Jongert, Erik; Roberts, Craig W; Gargano, Nicola; Förster-Wald, Elisabeth; Petersen, Eskild.

In: Memorias do Instituto Oswaldo Cruz, Vol. 104, No. 2, 03.2009, p. 252-266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vaccines against toxoplasma gondii

T2 - Memorias do Instituto Oswaldo Cruz

AU - Jongert, Erik

AU - Roberts, Craig W

AU - Gargano, Nicola

AU - Förster-Wald, Elisabeth

AU - Petersen, Eskild

PY - 2009/3

Y1 - 2009/3

N2 - Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects. Rodent models have been used in research on vaccines against T. gondii over the past decades. However, regardless of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is challenged with T. gondii, either directly or via a vector. Only a few live, attenuated T. gondii strains used for immunization have been able to confer protective immunity, which is measured by a lack of tissue cysts after challenge. Furthermore, challenge with low virulence strains, especially strains with genotype II, will probably be insufficient to provide protection against the more virulent T. gondii strains, such as those with genotypes I or II, or those genotypes from South America not belonging to genotype I, II or III. Future studies should use animal models besides rodents, and challenges should be performed with at least one genotype II T. gondii and one of the more virulent genotypes. Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to the traditional endpoint of survival or reduction in numbers of brain cysts after challenge.

AB - Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects. Rodent models have been used in research on vaccines against T. gondii over the past decades. However, regardless of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is challenged with T. gondii, either directly or via a vector. Only a few live, attenuated T. gondii strains used for immunization have been able to confer protective immunity, which is measured by a lack of tissue cysts after challenge. Furthermore, challenge with low virulence strains, especially strains with genotype II, will probably be insufficient to provide protection against the more virulent T. gondii strains, such as those with genotypes I or II, or those genotypes from South America not belonging to genotype I, II or III. Future studies should use animal models besides rodents, and challenges should be performed with at least one genotype II T. gondii and one of the more virulent genotypes. Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to the traditional endpoint of survival or reduction in numbers of brain cysts after challenge.

KW - toxoplasma gondii

KW - vaccine models

KW - vaccines

KW - virulence

KW - genotype

UR - http://www.scielo.br/scielo.php?pid=0074-0276&script=sci_serial

UR - http://dx.doi.org/10.1590/S0074-02762009000200019

U2 - 10.1590/S0074-02762009000200019

DO - 10.1590/S0074-02762009000200019

M3 - Article

VL - 104

SP - 252

EP - 266

JO - Memorias do Instituto Oswaldo Cruz

JF - Memorias do Instituto Oswaldo Cruz

SN - 1678-8060

IS - 2

ER -